Roberts Glore & Co. Inc. IL Acquires New Holdings in Cencora, Inc. $COR

Roberts Glore & Co. Inc. IL bought a new stake in Cencora, Inc. (NYSE:COR) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 1,716 shares of the company’s stock, valued at approximately $486,000.

A number of other large investors have also added to or reduced their stakes in the company. ExodusPoint Capital Management LP purchased a new stake in shares of Cencora during the fourth quarter valued at $16,487,000. Impact Partnership Wealth LLC acquired a new stake in Cencora during the 1st quarter worth about $1,170,000. SEB Asset Management AB purchased a new stake in Cencora during the 1st quarter valued at about $134,139,000. PFA Pension Forsikringsaktieselskab purchased a new stake in Cencora during the 4th quarter valued at about $59,145,000. Finally, Summit Global Investments acquired a new position in shares of Cencora in the second quarter valued at about $2,283,000. 97.52% of the stock is currently owned by institutional investors.

Insider Transactions at Cencora

In other Cencora news, Director Lauren M. Tyler purchased 550 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were purchased at an average cost of $270.23 per share, with a total value of $148,626.50. Following the completion of the purchase, the director owned 4,359 shares in the company, valued at approximately $1,177,932.57. This represents a 14.44% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Elizabeth S. Campbell sold 11,300 shares of the business’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the transaction, the executive vice president owned 19,455 shares in the company, valued at $6,305,754.60. The trade was a 36.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.38% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on COR shares. Weiss Ratings raised Cencora from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, August 6th. Morgan Stanley increased their price objective on shares of Cencora from $342.00 to $346.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Royal Bank Of Canada started coverage on Cencora in a research report on Wednesday, August 19th. They set a “sector perform” rating and a $330.00 price target for the company. Wells Fargo & Company boosted their target price on shares of Cencora from $331.00 to $395.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Finally, Citigroup reiterated a “buy” rating on shares of Cencora in a research report on Thursday, August 6th. Thirteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $370.85.

Cencora Stock Performance

NYSE COR opened at $328.28 on Wednesday. The company has a debt-to-equity ratio of 3.53, a current ratio of 0.93 and a quick ratio of 0.58. The stock’s 50 day simple moving average is $304.37 and its 200-day simple moving average is $311.24. The company has a market cap of $62.65 billion, a PE ratio of 24.39, a price-to-earnings-growth ratio of 1.86 and a beta of 0.57. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, topping the consensus estimate of $4.35 by $0.13. The firm had revenue of $84.75 billion during the quarter, compared to analysts’ expectations of $84.31 billion. Cencora had a return on equity of 125.45% and a net margin of 0.79%.The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the previous year, the business earned $4.00 earnings per share. As a group, equities research analysts anticipate that Cencora, Inc. will post 17.87 EPS for the current fiscal year.

Cencora announced that its Board of Directors has initiated a stock buyback plan on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 3.9% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its shares are undervalued.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Friday, August 14th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, August 14th. Cencora’s dividend payout ratio is 17.83%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.